Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 7,301–7,400 of 10,906
Chen, W., Lin, Y.-P., Cheng, C., Shen, C., Li, C., Wang, Y., Shih, T., Hong, C., Chang, T., & Shen, C. (2022) · Biosensors · doi:10.3390/bios12100891 · Cited by 4
COVID-19 Vaccination Outcomes at a Pediatric Long-Term Care Facility
Bickel, S. G., Harris, C. A., Huxol, H., et al. (2021) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003185 · Cited by 3
Funakoshi, Y., Yakushijin, K., Ohji, G., Matsutani, T., Doi, K., Sakai, H., Sasaki, T., Kusakabe, T., Matsumoto, S., Saito, Y., et al. (2024) · eJHaem · doi:10.1002/jha2.932 · Cited by 4
Li, Z., He, H., Li, H., Zhang, F., Jin, X., Liu, S., Chen, M., Li, Y., & Zhuang, J. (2024) · International Journal of Cancer · doi:10.1002/ijc.35063 · Cited by 4
Tsyruk, O., Kaplan, G. G., Fortin, P. R., Hitchon, C. A., Chandran, V., LARCHÉ, M. J., Aviña-Zubieta, A., Boire, G., Colmegna, I., Lacaille, D. V., et al. (2024) · Vaccines · doi:10.3390/vaccines12091027 · Cited by 3
School Asthma Care During COVID-19: What We Have Learned and What We Are Learning
Abrams, E. M., Jordan, K., & Szefler, S. J. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.11.020 · Cited by 3
The Role of SARS-CoV-2 Spike Protein in the Growth of Cervical Cancer Cells
Willson, C. M., Lequio, M., Zhu, Z., Wakefield, M. R., Bai, Q., Fajardo, E., XIAO, H., Leung, S., & Fang, Y. (2024) · Anticancer Research · doi:10.21873/anticanres.16982 · Cited by 6
Association of COVID-19 Case-Fatality Rate With State Health Disparity in the United States
Lee, Y.-C., Chang, K.-Y., & Mirsaeidi, M. S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.853059 · Cited by 2
Kanizsai, A., Závori, L., Molnár, T., Tökés‐Füzesi, M., Szalai, Z., Berecz, J., Várnai, R., Péterfi, Z., Schwarcz, A., & Csécsei, P. (2023) · Vaccines · doi:10.3390/vaccines11010182 · Cited by 5
Vaccine-associated axillary lymphadenopathy with a focus on COVID-19 vaccines
Wilpert, C., Wenkel, E., Baltzer, P., Fallenberg, E. M., Preibsch, H., Sauer, S. T., Siegmann-Luz, K., Weigel, S., Wunderlich, P., & Wessling, D. (2024) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-2328-7536 · Cited by 3
Sasaki, N., Kuroda, R., Tsuno, K., Imamura, K., & Kawakami, N. (2022) · Journal of Occupational Health · doi:10.1002/1348-9585.12356 · Cited by 3
Nanoparticle targeting strategies for traumatic brain injury
Flores-Prieto, D. E. E., & Stabenfeldt, S. E. (2024) · Journal of Neural Engineering · doi:10.1088/1741-2552/ad995b · Cited by 5
Choi, S.-J., Kim, S.-H., Han, M. S., Yoon, Y., Kim, Y. K., Cho, H., Yun, K. W., Song, S. H., Ahn, B., Kim, Y. K., et al. (2023) · Immune Network · doi:10.4110/in.2023.23.e33 · Cited by 3
DNA-based vaccines: Advances, applications, and future prospects
Zhou, Z. P., Chen, Z. R., Bandara, R. A., Duan, R. C., Cao, H., Liu, J., & Hu, J. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2025.102025 · Cited by 9
“The COVID-19 pandemic catalyzed unprecedented investment and research in nucleic acid-based vaccines, resulting in the Emergency Use Authorization (EUA) of several mRNA vaccines 5,6 and Ad vector-based DNA vaccines.”
Worth a shot? The political economy of government responsiveness in times of crisis
Gutiérrez, E., Meriläinen, J., & de León, M. P. (2024) · World Development · doi:10.1016/j.worlddev.2024.106762 · Cited by 5
Review of current vaccine development platform to prevent coronavirus disease
Arif, K., Malhotra, S., Mohammad, S., Fatima, S., Farooqui, S., & Saleem, M. (2022) · National Journal of Maxillofacial Surgery · doi:10.4103/njms.njms_454_21 · Cited by 3
Li, J., Liu, Y., Ma, X., Liu, S., Yang, C., Zhang, Y., Cheng, X., Wen, Y., Mi, S., Zu, H., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adw6105 · Cited by 4
Scotto, R., Lanzardo, A., Buonomo, A., Pinchera, B., Cattaneo, L., Sardanelli, A., Mercinelli, S., Viceconte, G., Perrella, A., Esposito, V., et al. (2022) · Vaccines · doi:10.3390/vaccines10122043 · Cited by 2
Transient Myopericarditis Following Vaccination for COVID-19
Gill, J., Mallari, A. J. P., & Zahra, F. (2022) · Journal of Medical Cases · doi:10.14740/jmc3876 · Cited by 4
A case of cutaneous sarcoidosis with pulmonary involvement after SARS-CoV-2 mRNA vaccination
Seol, J. E., Jang, S. H., Yun, H. W., et al. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.05.019 · Cited by 3
Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects
Feng, G., Zhang, L., Wang, K., Chen, B., & Xia, H. H. (2021) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2021.00004 · Cited by 4
Vaccination in old age: Challenges and promises
Caruso, C., Aiello, A., Pawelec, G., & Ligotti, M. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822569-1.00020-2 · Cited by 4
Roberts, C. H., Brindle, H. E., Rogers, N. T., et al. (2021) · medRxiv · doi:10.1101/2021.07.13.21260425 · Cited by 3
COVID-19 Vaccine and Fitness to Fly
Gabbai, D., Ekshtein, A., Tehori, O., Ben‐Ari, O., & Shapira, S. (2021) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.5882.2021 · Cited by 3
Exploring immunotherapeutic strategies for bacterial and viral diseases
Adedokun, A. I., Adigun, O. A., Ibrahim, A. M., Idris, I., Ntasin, P. Y., Olowu, B. I., Ikele, C. M.-C., Precious, F. K., Dibia, E. O., Okesanya, O. J., et al. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003202 · Cited by 8
Efficacy of early use of remdesivir: a systematic review of subgroup analysis
Gil‐Sierra, M. D., Briceño-Casado, M. D. P., Rey, E. J. A. D., & Sánchéz‐Hidalgo, M. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/154.2021 · Cited by 4
Turabián, J. L. (2021) · Epidemiology International Journal · doi:10.23880/eij-16000204 · Cited by 4
Salbaş, E., Öcek, Ö., Öcek, L., et al. (2021) · Ege Tıp Bilimleri Dergisi · doi:10.33713/egetbd.969419 · Cited by 3
Severe acute respiratory syndrome coronavirus 2
CABI (2021) · CABI Compendium · doi:10.1079/cabicompendium.18471793 · Cited by 3
Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
Tandler, C., Heitmann, J., Michel, T., Marconato, M., Jaeger, S., Tegeler, C. M., Denk, M., Richter, M., Oezbek, M. T., Maringer, Y., et al. (2023) · medRxiv · doi:10.1101/2023.06.07.23291074 · Cited by 16
Magoola, M., & Niazi, S. K. (2025) · Vaccines · doi:10.3390/vaccines13090970 · Cited by 11
“Recent studies demonstrate that modified pathogen antigens can overcome pre-existing immunity through influenza studies, COVID-19 vaccine experience, and other clinical evidence [51] (Table 6).”
Impfung gegen SARS-CoV-2 bei Krebspatienten
von Lilienfeld‐Toal, M., Rieger, C. T., Giesen, N., & Wormann, B. J. (2021) · Der Onkologe · doi:10.1007/s00761-021-00972-1 · Cited by 3
Effects of Biological Sex and Pregnancy on SARS-CoV-2 Pathogenesis and Vaccine Outcomes
Shapiro, J. R., Roberts, C. W., Arcovio, K., Reade, L., Klein, S. L., & Dhakal, S. (2023) · Current topics in microbiology and immunology · doi:10.1007/978-3-031-35139-6_4 · Cited by 8
Sex-biased immunogenicity of a mucosal subunit vaccine against SARS-CoV-2 in mice
Li, J., Hsu, K. S., Howe, S. E., Hoang, T. N., Zheng, X., Berzofsky, J. A., & Sui, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1386243 · Cited by 4
Hybrid fibrous architectures-mediated gene transfer by pDNA nanoparticles into macrophages
Ghițman, J., Pîrcălăbioru, G. G., Deleanu, C., Vasile, E., Iliescu, C., & Iovu, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38071 · Cited by 3
Wang, C., & Young, Y. (2023) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2023.103970 · Cited by 3
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster
Wachter, B. T., Xu, Q., Shi, L., Burbelo, P. D., Myint-Hpu, K., Schwartzberg, P. L., Rehman, M. T., Dewar, R. L., Boswell, K. L., Koup, R. A., et al. (2025) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2025.02.026 · Cited by 4
Sharabrin, S. V., Krasnikova, S. I., Kisakov, D. N., Borgoyakova, M. B., Yakovlev, V. A., Tigeeva, E. V., Starostina, E. V., Litvinova, V. R., Kisakova, L. A., Vahitov, D. I., et al. (2026) · Vaccines · doi:10.3390/vaccines14010056 · Cited by 4
“Another important advantage is the efficient activation of both humoral and cellular virus-specific immunity, since the target protein is expressed endogenously from mRNA [12,13].”
Woman with pruritic rash and dermatographism
Malcolm, T. R., & Shah, Y. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12709 · Cited by 2
Principi, M., Macaluso, F. S., Todeschini, A., Facciotti, F., Contaldo, A., Castiglione, F., Nardone, O. M., Spagnuolo, R., Doldo, P., Riguccio, G., et al. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002550 · Cited by 3
Jin, Z., Wu, J., Wang, Y., Huang, T., Zhao, K., Liu, J., Wang, H., Zhu, T., Gou, J.-B., Huang, H., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.10.012 · Cited by 6
Veereman, G., & Bronský, J. (2021) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003260 · Cited by 3
Lu, N., Li, Z., Su, D., Chen, J., Zhao, J., Gao, Y. H., Liu, Q., Liu, G., Luo, X., Luo, R., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124344 · Cited by 4
Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients
Oganesyan, A. V., Menzulin, R., Surovoy, Y. A., Nikiforchin, A., & Zykov, K. A. (2021) · Critical Care Research and Practice · doi:10.1155/2021/5557302 · Cited by 4
Bennett, C., Hoosain, Z., Koen, A. L., Lalloo, U., Louw, C. E., Maluleke, V. L., Patel, F., Benadé, G., Venter, E. L., Galbiati, S., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106285 · Cited by 3
Parente, R., Sartorio, S., Brussino, L., Pasquale, T. D., Zoli, A., Agolini, S., Agosta, E. D., Quattrocchi, P., Borrelli, P., Bignardi, D., et al. (2023) · Vaccines · doi:10.3390/vaccines11040852 · Cited by 3
Tamar Schlick, A., & Yan, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821978-2.00118-5 · Cited by 3
Myocardial Injury Related to SARS-CoV-2 mRNA Vaccination: The Plot Thickens
Levi, N., & Hasin, T. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3013 · Cited by 3
COVID-19 vaccine type controls stromal reprogramming in draining lymph nodes
Fair-Mäkelä, R., Thorén, P., Näsiaho, J., Sundqvist, P., Piiroinen, I., Kähäri, L., Julkunen, I., Ivaska, J., Hub, E., Rot, A., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adr6787 · Cited by 6
Takalani, A., Robinson, M., Jonas, P., Bodenstein, A., Sambo, V., Jacobson, B. F., Louw, V. J., Opie, J., Peter, J., Rowji, P., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.066 · Cited by 3
Grant, M. D., Bentley, K., Fielding, C. A., Hatfield, K. M., Ings, D. P., Harnum, D. O. A., Wang, E. C. Y., Stanton, R. J., & Holder, K. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.09.531709 · Cited by 3
Efficacy and safety of four COVID-19 vaccines in preventing SARS-CoV-2 infection: A rapid review
Morón-Duarte, L. S., Acevedo, K. R. C., Gutiérrez, M. P., Siegler, I. H. D. L. H., & Yomayusa, N. (2022) · Biomédica · doi:10.7705/biomedica.6254 · Cited by 5
Wang, Z., Muto, R., Miyoshi, H., et al. (2023) · Pathology International · doi:10.1111/pin.13398 · Cited by 3
Deng, H., Li, Y., Wang, G., & Li, R. (2025) · Biology · doi:10.3390/biology14010067 · Cited by 3
liu, A., Necela, B. M., Li, Z., Cogen, D., Wieczorek, M. A., Mummareddy, A., Acampora, M., Reynolds, G. A., Advani, P. P., Moreno-Aspitia, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690495 · Cited by 3
Yang, C., Li, E., Guo, X., Xie, W., Wang, Y., Huang, X., Chiu, S., & Wu, X. (2025) · ACS Nano · doi:10.1021/acsnano.4c17269 · Cited by 3
COVID-19 in Relation to Polypharmacy and Immunization (2020–2024)
Puigdellívol‐Sánchez, A., Juanes-González, M., Calderón-Valdiviezo, A., Valls-Foix, R., González-Salvador, M., Lozano-Paz, C., & Vidal‐Alaball, J. (2024) · Viruses · doi:10.3390/v16101533 · Cited by 3
COVID-19-Related Predictors of Fear and Attitude to Vaccination Displayed by Polish Students
Bartosiewicz, A., Łuszczki, E., Bartosiewicz, A., Dereń, K., Oleksy, Ł., & Stolarczyk, A. (2022) · Vaccines · doi:10.3390/vaccines10091524 · Cited by 3
Equity and evidence during vaccine rollout: stepped wedge cluster randomised trials could help
Bell, K., Glasziou, P., Stanaway, F., Bossuyt, P. M., & Irwig, L. (2021) · BMJ · doi:10.1136/bmj.n435 · Cited by 4
Zhang, Y., Liu, X.-Z., Zhang, Z., Zhou, T., Zhang, X., Yang, H.-Y., Tan, M., Hu, N., Shi, S.-F., Wang, F., et al. (2021) · National Science Review · doi:10.1093/nsr/nwac034 · Cited by 3
COVID-19 vaccine immunity in oncology patients
Uslu, G. H., Rakıcı, S. Y., & Yazıcı, Z. A. (2023) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2023_030 · Cited by 4
Rakhshan, S. A., Zaj, M., Ghane, F. H., & Nejad, M. S. (2024) · Physical review. E · doi:10.1103/physreve.109.014212 · Cited by 4
COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants
Selvam, S. P., Ramani, P., Ramya, R., Sundar, S., & Lakshmi, T. A. (2022) · Cureus · doi:10.7759/cureus.24927 · Cited by 5
Muscle-targeting LNP vaccines enable potent immune responses against varicella zoster virus
Zhang, H., Ma, J., Jin, L., Ma, Y., Dong, K., Li, J., Yu, F., & Song, G. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01961-2 · Cited by 4
Gennari, A. G., Rossi, A., Sartoretti, T., Maurer, A. B., Skawran, S., Treyer, V., Sartoretti, E., Fontecedro, A. C., Schwyzer, M., Waelti, S. L., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-44215-2 · Cited by 3
Ukey, R., Bruiners, N., Mishra, H., Mishra, P., McCloskey, D., Onyuka, A., Chen, F., Pinter, A., Weiskopf, D., Sette, A., et al. (2021) · medRxiv · doi:10.1101/2021.09.17.21263528
Boyce, T. G., McClure, D. L., Hanson, K. E., Daley, M. F., DeSilva, M. B., Irving, S. A., Jackson, L. A., Klein, N. P., Lewin, B. J., Williams, J. T. B., et al. (2024) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5863 · Cited by 4
A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues
Wu, B., Liu, Y., Zhang, X., Luo, D., Wang, X., Qiao, C., & Liu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420216 · Cited by 7
Osaka, T., Yamamoto, Y., Takehisa, S. O. M. A., Yanagisawa, N., & Nagata, S. (2023) · Microorganisms · doi:10.3390/microorganisms11020471 · Cited by 3
Kobayashi, M., Mori, A., Onozawa, M., Tsukamoto, S., Senjo, H., Ishio, T., Yokoyama, E., Kanaya, M., Izumiyama, K., Saito, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05142-4 · Cited by 4
Comparison of Adverse Effects of COVID-19 Vaccines Among Elderly: Pfizer/BioNTech Versus CoronaVac
Evren, H., Evren, E. Ü., Barış, S. A., İNCE, F. G., SOYDAN, C., Elci, Ö. C., & Yıldız, F. (2023) · Acibadem Universitesi Saglik Bilimleri Dergisi · doi:10.31067/acusaglik.1076933 · Cited by 3
de Jong, R., Zhou, F., Andersen, T. K., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01341-4 · Cited by 3
Rastegar-Kashkouli, A., Jafari, M., & Yousefi, P. (2022) · Journal of Renal Endocrinology · doi:10.34172/jre.2022.25064 · Cited by 3
Peled, Y., Patel, J. K., Raanani, E., Ram, E., Fardman, A., Beigel, R., Atari, N., Kliker, L., Elkader, B. A., Mandelboim, M., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.15091 · Cited by 3
Dickson, A. M., Geerling, E., Stone, E. T., Hassert, M., Steffen, T. L., Makkena, T., Smither, M., Schwetye, K. E., Zhang, J., Georges, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188392 · Cited by 3
Computational investigation of peptidomimetics as potential inhibitors of SARS-CoV-2 spike protein
Ibrahim, M. T., & Tao, P. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2116601 · Cited by 4
Carr, E. J., Townsley, H., Wu, M., Wilkinson, K. A., Hobson, P. S., Levi, D., Namjou, S., Mears, H. V., Hobbs, A., Ragno, M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.24.541920 · Cited by 3
Belete, T. M. (2022) · The Open Microbiology Journal · doi:10.2174/18742858-v16-e2201240 · Cited by 3
Non-pharmaceutical interventions and inoculation rate shape SARS-CoV-2 vaccination campaign success
Galanti, M., Pei, S., Yamana, T. K., Angulo, F. J., Charos, A., Khan, F. L., Shea, K. M., Swerdlow, D. L., & Shaman, J. L. (2021) · Epidemiology and Infection · doi:10.1017/s095026882100217x · Cited by 4
Ryu, S., Kim, J., Lee, J., Kang, Y.-S., Shin, H., Jung, S., Kim, J., & Kim, S. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e234 · Cited by 3
Pavlidis, G., Giannoulis, V., Pirounaki, M., Lampropoulos, I. C., Siafi, E. P., Nitsa, A., Pavlou, E. G., Xanthaki, A., Perlepe, G., Fortis, S. P., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13060910 · Cited by 4
Ashique, S., Kumar, S., Kumar, H., Roy, J., Pal, S., & Pal, S. (2023) · Indian Journal of Health Sciences and Biomedical Research · doi:10.4103/kleuhsj.kleuhsj_505_22 · Cited by 2
Partial or full doses first? Vaccine allocation under limited supply
Hu, M., Zhang, C., & Zhou, Y. (2026) · Production and Operations Management · doi:10.2139/ssrn.4411818 · Cited by 6
Merling, M. R., Williams, A. M., Mahfooz, N. S., Ruane-Foster, M., Smith, J. W., Jahnes, J., Ayers, L. W., Bazan, J. A., Norris, A. H., Turner, A. N., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011596 · Cited by 4
Choi, G., Lim, A., Choi, S., Park, K., Lee, S. Y., & Kim, J. (2022) · Epidemiology and Health · doi:10.4178/epih.e2023008 · Cited by 3
Ohmura, S., Yonezawa, H., Yukishima, T., Gohto, Y., & Obana, A. (2024) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxae042 · Cited by 5
Johnston, T. S., Li, S. H., Painter, M. M., Swaminathan, D., Atkinson, R. K., Dadonaite, B., Wang, S., Douek, N. R., Kampman, L., Schlesinger, R., et al. (2026) · Nature Immunology · doi:10.1038/s41590-026-02613-4 · Cited by 4
“These vaccines demonstrated high early efficacy, preventing an estimated 19.8 million deaths in their first year of use 4,5 .”
InfluentialMakan, N., Madhi, S. A., & Dangor, Z. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2471-6906 · Cited by 4
An Update on Coronavirus Disease-19 Vaccines
Gupta, M., & Kapoor, I. (2021) · Journal of Medical Evidence · doi:10.4103/jme.jme_16_21 · Cited by 3
Bordry, N., Mamez, A., Fedeli, C., Cantero, C., Jaksic, C., Ustero, P., Rayroux, C., Berra, G., Portillo, V., Puntel, M., et al. (2023) · Vaccines · doi:10.3390/vaccines11081284 · Cited by 3
Evaluation of a Lateral Flow Immunoassay COVIDTECH® SARS-CoV-2 IgM/IgG Antibody Rapid Test
Exinger, J., Hartard, C., Lafferrière, F., Fenninger, C., Charbonnière, L. J., & Jeulin, H. (2021) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2021.273 · Cited by 3
Review of SARS-CoV-2 Antigen and Antibody Testing in Diagnosis and Community Surveillance
Nerenz, R. D., Hubbard, J. A., & Cervinski, M. A. (2022) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2022.09.018 · Cited by 6
Pan, Y., Chandrashekaran, I. R., Tennant, L., Rossjohn, J., & Littler, D. R. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283194 · Cited by 3
Estimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials
Michiels, H., Vandebosch, A., & Vansteelandt, S. (2022) · Statistical Communications in Infectious Diseases · doi:10.1515/scid-2022-0003 · Cited by 3
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.